IOL with drug delivery devices and uninterrupted PCO barrier edge
Inventors
Cable, II, Craig Alan • Sussman, Glenn R. • Dennewill, James R. • Kahook, Malik Y.
Assignees
University of Colorado Boulder • University of Colorado Colorado Springs • Spyglass Pharma Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11654014-B2
Publication Date
2023-05-23
Expiration Date
Abstract
An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.
Core Innovation
An ophthalmic implant includes an intraocular lens (IOL) with a lens and a haptic integrally formed with the lens and extending outwards therefrom. The IOL includes an anterior surface, a posterior surface, and a circumferential side wall, wherein the posterior surface joins the circumferential side wall in a sharply angular edge that defines a plane of the sharply angular edge. A drug delivery device is provided with an anterior panel and an aperture configured to receive a portion of the haptic therein, and the drug delivery device is configured and disposed on the haptic such that a posterior-most surface of the drug delivery device is anteriorly displaced from the plane.
In additional configurations, the ophthalmic implant includes an IOL having first and second haptics extending outwards from the lens, each with a posterior surface joining a circumferential side wall in a sharply angular edge that defines a plane. A first and a second drug delivery device are disposed on the first and second haptics, respectively, each including an anterior panel. The posterior-most surface of the first and second drug delivery devices is anteriorly displaced from the plane.
The implant further includes geometric and functional constraints intended to preserve formation of a PCO barrier around the periphery. In one aspect, the posterior-most surface of the drug delivery device is positioned anterior to a reference defined by the plane of the sharply angular edge so that the PCO barrier is uninterrupted around an entire periphery. In other refinements, the drug delivery device includes or cooperates with its own sharply angular edge relative to a barrier plane, and the implant includes features that inhibit rotation, prevent outward migration, and improve stability.
Claims Coverage
The independent claims are directed to an ophthalmic implant that combines an IOL with sharply angular posterior edges and one or more drug delivery devices mounted on haptics with posterior-most surfaces anteriorly displaced from a reference plane. The claim set is refined by additional inventive features that constrain edge geometry, payload options, and structural/placement relationships intended to preserve PCO barrier formation and inhibit undesirable movement.
Sharply angular posterior edge plane with anteriorly displaced drug device posterior-most surface
An ophthalmic implant comprising an IOL including a lens with an integrally formed haptic extending outwards, where the posterior surface joins a circumferential side wall in a sharply angular edge defining a plane, and a drug delivery device with an anterior panel and an aperture configured to receive a portion of the haptic, the drug delivery device disposed on the haptic such that a posterior-most surface of the drug delivery device is anteriorly displaced from the plane.
First and second haptics with first and second drug delivery devices anteriorly displaced from the sharply angular edge plane
An ophthalmic implant comprising an IOL with first and second haptics, where the posterior surface joins the circumferential side wall in a sharply angular edge defining a plane, and first and second drug delivery devices disposed on the first and second haptics, each including an anterior panel, where the posterior-most surface of the first and second drug delivery devices is anteriorly displaced from the plane.
Across the independent claims, the core coverage is the association of sharply angular IOL posterior edges (defining a plane) with drug delivery devices mounted on haptics such that the drug device posterior-most surface is anteriorly displaced from that plane. Dependent features further constrain the sharply angular edge geometry, specify keyed or structural engagement between the haptics and drug devices to inhibit rotation and constrain device behavior, and include constraints relating to not disrupting PCO barrier formation, along with enumerated therapeutic agent categories.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?